Transcriptional Regulation of Fibroblast Growth Factor 21 Expression.
10.3803/EnM.2014.29.2.105
- Author:
Kwi Hyun BAE
1
;
Jung Guk KIM
;
Keun Gyu PARK
Author Information
1. Division of Endocrinology and Metabolism, Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea. kpark@knu.ac.kr
- Publication Type:Review
- Keywords:
Fibroblast growth factor 21;
Transcription factors;
Diabetes mellitus;
Insulin resistance
- MeSH:
Diabetes Mellitus;
Fibroblast Growth Factors*;
Gene Expression;
Glucose;
Insulin Resistance;
Lipid Metabolism;
Metabolic Diseases;
Obesity;
Transcription Factors
- From:Endocrinology and Metabolism
2014;29(2):105-111
- CountryRepublic of Korea
- Language:English
-
Abstract:
Fibroblast growth factor 21 (FGF21) is an attractive target for treating metabolic disease due to its wide-ranging beneficial effects on glucose and lipid metabolism. Circulating FGF21 levels are increased in insulin-resistant states; however, endogenous FGF21 fails to improve glucose and lipid metabolism in obesity, suggesting that metabolic syndrome is an FGF21-resistant state. Therefore, transcription factors for FGF21 are potential drug targets that could increase FGF21 expression in obesity and reduce FGF21 resistance. Despite many studies on the metabolic effects of FGF21, the transcriptional regulation of FGF21 gene expression remains controversial and is not fully understood. As the FGF21 transcription factor pathway is one of the most promising targets for the treatment of metabolic syndrome, further investigation of FGF21 transcriptional regulation is required.
